[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100467171":3},{"organization":4,"armGroups":7,"interventions":32,"overallOfficials":47,"centralContacts":52,"locations":61,"responsibleParty":169,"collaborators":38,"id":171,"slug":172,"hasResults":173,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":38,"eligibilityCriteria":177,"healthyVolunteers":173,"sex":178,"minAge":179,"maxAge":38,"enrollmentInfo":180,"targetDuration":38,"studyType":183,"phases":184,"briefSummary":186,"conditions":187,"keywords":191,"overallStatus":64,"whyStopped":38,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":208},{"fullName":5,"class":6},"Advenchen Laboratories, LLC","INDUSTRY",[8,14,19,24,28],{"label":9,"type":10,"description":11,"interventionNames":12},"OBD finding cohort at low dose--completed","EXPERIMENTAL","Subject in low dose group will receive AL8326 orally in each cycle until intolerable toxicity or disease progression or withdrawal . 6-12 subjects are in this group. Efficacy, safety and PK will be evaluated and compared within 3 different dosing group to define the final OBD.",[13],"Drug: AL8326 40 mg",{"label":15,"type":10,"description":16,"interventionNames":17},"OBD finding cohort at middle dose--completed","Subject in middle dose group will receive AL8326 orally in each cycle until intolerable toxicity or disease progression or withdrawal . 6-12 subjects are in this group. Efficacy, safety and PK will be evaluated and compared within 3 different dosing group to define the final OBD.",[18],"Drug: AL8326 60 mg",{"label":20,"type":10,"description":21,"interventionNames":22},"OBD finding cohort at high dose--completed","Subject in high dose group will receive AL8326 orally in each cycle until intolerable toxicity or disease progression or withdrawal . 6-12 subjects are in this group. Efficacy, safety and PK will be evaluated and compared within 3 different dosing group to define the final OBD.",[23],"Drug: AL8326 80 mg--stopped",{"label":25,"type":10,"description":26,"interventionNames":27},"Non-Small Cell Lung(NSCLC)","≥2nd line NSCLC patient in 40 mg dose",[13],{"label":29,"type":10,"description":30,"interventionNames":31},"Renal Cell Carcinoma( RCC )","≥2nd line RCC patient in 60 mg dose",[18],[33,39,43],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"DRUG","AL8326 40 mg","Taken AL3826 at 40mg QD orally",[25,9],null,{"type":34,"name":40,"description":41,"armGroupLabels":42,"otherNames":38},"AL8326 60 mg","Taken AL3826 at 60mg QD orally",[15,29],{"type":34,"name":44,"description":45,"armGroupLabels":46,"otherNames":38},"AL8326 80 mg--stopped","Taken AL3826 at 80 mg QD orally",[20],[48],{"name":49,"affiliation":50,"role":51},"Saiama Waqar, MD","Washington University School of Medicine","PRINCIPAL_INVESTIGATOR",[53,58],{"name":54,"role":55,"phone":56,"phoneExt":38,"email":57},"Shiying Sprinzl","CONTACT","805-530-1550","shiyings@advenchen.com",{"name":59,"role":55,"phone":56,"phoneExt":38,"email":60},"Judy Chen","Judyc@advenchen.com",[62,83,94,105,122,138,155],{"facility":63,"status":64,"city":65,"state":66,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"University of Alabama at Birmingham","RECRUITING","Birmingham","Alabama","35294","United States","US",{"type":71,"coordinates":72},"Point",[73,74],-86.80249,33.52066,{"lat":74,"lon":73},[77,81],{"name":78,"role":55,"phone":79,"phoneExt":38,"email":80},"Clinical Research Manager","205-934-6454","annaburton@uabmc.edu",{"name":82,"role":51,"phone":38,"phoneExt":38,"email":38},"Aakash Desai, MD",{"facility":84,"status":85,"city":86,"state":87,"zip":88,"country":68,"countryCode":69,"cosmosGeoPoint":89,"geoPoint":93,"contacts":38},"Cleveland Clinic Florida","WITHDRAWN","Weston","Florida","33331",{"type":71,"coordinates":90},[91,92],-80.39977,26.10037,{"lat":92,"lon":91},{"facility":95,"status":96,"city":97,"state":98,"zip":99,"country":68,"countryCode":69,"cosmosGeoPoint":100,"geoPoint":104,"contacts":38},"Northwestern University","COMPLETED","Chicago","Illinois","60611",{"type":71,"coordinates":101},[102,103],-87.65005,41.85003,{"lat":103,"lon":102},{"facility":106,"status":64,"city":107,"state":108,"zip":109,"country":68,"countryCode":69,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"Siteman Cancer Center, Washington University","St Louis","Missouri","63130",{"type":71,"coordinates":111},[112,113],-90.19789,38.62727,{"lat":113,"lon":112},[116,119,121],{"name":38,"role":55,"phone":117,"phoneExt":38,"email":118},"314-747-7222","Patient_Care_Coordination_Center@bjc.org",{"name":38,"role":55,"phone":120,"phoneExt":38,"email":38},"800-600-3606",{"name":49,"role":51,"phone":38,"phoneExt":38,"email":38},{"facility":123,"status":64,"city":124,"state":125,"zip":126,"country":68,"countryCode":69,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Cleveland Clinic","Cleveland","Ohio","44195",{"type":71,"coordinates":128},[129,130],-81.69541,41.4995,{"lat":130,"lon":129},[133,136],{"name":134,"role":55,"phone":135,"phoneExt":38,"email":38},"Cancer Answer Line (Taussig)","216-444-7923",{"name":137,"role":51,"phone":38,"phoneExt":38,"email":38},"Lukas Delasos, MD",{"facility":139,"status":64,"city":140,"state":38,"zip":38,"country":141,"countryCode":142,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"Hospital Universitari Vall d'Hebron","Barcelona","Spain","ES",{"type":71,"coordinates":144},[145,146],2.15899,41.38879,{"lat":146,"lon":145},[149,153],{"name":150,"role":55,"phone":151,"phoneExt":38,"email":152},"clinical study coordicator","• +34932746000","pedrorocha@vhio.net",{"name":154,"role":51,"phone":38,"phoneExt":38,"email":38},"Pedro Filipe Simoees Da Rocha, MD",{"facility":156,"status":64,"city":157,"state":38,"zip":38,"country":141,"countryCode":142,"cosmosGeoPoint":158,"geoPoint":162,"contacts":163},"Hospital Universitario Ramón Y Cajal","Madrid",{"type":71,"coordinates":159},[160,161],-3.70256,40.4165,{"lat":161,"lon":160},[164,167],{"name":165,"role":55,"phone":166,"phoneExt":38,"email":38},"Cliical study coordinator","(+34) 91 3368831",{"name":168,"role":51,"phone":38,"phoneExt":38,"email":38},"María Eugenia Olmedo García, MD",{"type":170,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR","100467171","phase-2-phase-2-study-for-the-patient-who-has-diagnosed-with-small-cell-lung-cancer-sclc-or-non-small-cell-lung-cancer-nsclc-or-renal-cell-carcinoma-rcc-and-finished-the-first-line-stand-treatment--need-more-treatment-100467171",false,"NCT05363280","Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment","A Phase 2 Evaluation of the Safety and Efficacy of Veonetinib (AL8326) in ≥2nd Line Small Cell Lung Cancer (SCLC), Non Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC) Treatment","Major Inclusion Criteria:\n\n1. Male or female, 18 years of age or older\n2. ECOG performance status of 0 or 1\n3. Histologically or cytologically confirmed SCLC \u002FNSCLC\u002FRCC\n4. Have at least 1 lesion that meets the criteria for being measurable, as defined by RECIST 1.1\n5. Have a life expectancy of at least 3 months\n\nMajor Exclusion Criteria:\n\n1. Serious, non-healing wound, ulcer or bone fracture\n2. Major surgical procedure within 28 days or minor surgical procedure performed within 7 days prior to treatment\n3. Active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels\n4. Clinically significant cardiovascular disease including uncontrolled hypertension; myocardial infarction or unstable angina within 6 months prior to enrollment; New York Heart Association (NYHA) Grade II or greater congestive heart failure serious cardiac arrhythmia requiring medication; and Grade II or greater peripheral vascular disease\n5. Hemoptysis within 3 months prior to enrollment\n6. Concomitant treatment with strong inhibitors or inducers of CYP3A4, CYP2C9 and CYP2C19 within 14 days prior to enrollment and during the study unless there is an emergent or life-threatening medical condition that required it.\n\nMore information available upon request","ALL","18 Years",{"count":181,"type":182},80,"ESTIMATED","INTERVENTIONAL",[185],"PHASE2","This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non-Small Cell Lung (NSCLC) and Renal Cell Carcinoma patients who need ≥2nd line treatment .",[188,189,190],"Small Cell Lung Cancer","Renal Cell Carcinoma (RCC)","Non-Small Cell Lung",[192,193,194,195,196,197],"Recurrent small cell lung caner","Advanced small cell lung cancer","Metastatic Small lung cancer","≥2nd Line treatment","Non small cell lung cancer","Renal Cell Carcinoma","2026-05-05",{"date":200,"type":201},"2026-05-08","ACTUAL",{"date":203,"type":201},"2022-11-01",{"date":205,"type":182},"2028-12",{"name":207,"class":6},"Advenchen Pharmaceuticals, LLC.",7]